LXEO logo

LXEO
Lexeo Therapeutics Inc.

607
Mkt Cap
$403.6M
Volume
666,771.00
52W High
$10.99
52W Low
$2.72
PE Ratio
-3.53
LXEO Fundamentals
Price
$5.14
Prev Close
$5.08
Open
$5.12
50D MA
$5.77
Beta
2.01
Avg. Volume
979,399.30
EPS (Annual)
-$1.86
P/B
1.65
Rev/Employee
$0.00
$358.82
Loading...
Loading...
News
all
press releases
Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday
Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-lexeo-therapeutics-inc-stock...
MarketBeat
News Placeholder
More News
News Placeholder
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Brokerages
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one...
MarketBeat
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen cut Lexeo Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Should You Buy?
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Here's What Happened...
MarketBeat
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $312,950.00 in Stock
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average...
MarketBeat
News Placeholder
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 55,000 Shares of Stock
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the firm's stock in a transaction dated Monday, April 6th. The shares were sold at an average...
MarketBeat
News Placeholder
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are presently covering the stock, MarketBeat.com...
MarketBeat
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Issues Quarterly Earnings Results
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.03...
MarketBeat
News Placeholder
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday
Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 23. (View Earnings Report at...
MarketBeat
News Placeholder
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts
Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten brokerages that are currently covering the company, Marketbeat...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available